TomoTherapy Incorporated Announces Strategic Alliance with PTW
Advanced Quality Assurance System for Helical IMRT will be Unveiled at ASTRO 2007
MADISON, WI – TomoTherapy Incorporated (NASDAQ: TTPY), developer of the TomoTherapy® Hi·Art® treatment system for helical intensity-modulated radiation therapy (IMRT), announced today a strategic alliance with PTW, provider of advanced dosimetry and quality assurance equipment for radiation therapy. The alliance will enable TomoTherapy treatment centers worldwide to verify patient-specific treatment plans with added convenience and efficiency.
“This is another important step for us,” said Peter Hoban, senior product manager for TomoTherapy Incorporated. “PTW is an innovative company, providing state-of-the-art quality assurance equipment. This alliance helps TomoTherapy add QA options and workflow enhancements to our integrated platform.”
Through the TomoTherapy-PTW alliance, a suite of quality assurance products will be made available to hospitals and cancer centers using TomoTherapy’s helical IMRT. The PTW products include the seven29 Ion Chamber Array and the Octavius Octagonal Phantom for film-less, patient-specific quality assurance, as well as the MP3-T Water Phantom for Hi·Art treatment system quality assurance.
“We have developed these tools for the future of IMRT, so it is a natural for us to partner with TomoTherapy,” stated Richard Barker, general manager of PTW. “Together, we can ensure consistent precision of the most sophisticated treatment plans in radiation therapy.”
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Forward-Looking Statements
Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “will” or “can” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
17 Oct 2007
| Investor Contact: Thomas E. Powell Chief Financial Officer 608.824.2800 tpowell@tomotherapy.com |
Media Contact: Kevin O’Malley Manager Corporate Communications 608.824.2800 komalley@tomotherapy.com |
